Alys Pharmaceuticals chair Francesco De Rubertis (L) and COO Thibaud Portal
February 11, 2024 07:00 PM ESTUpdated 08:34 AM
Financing
Startups

Centes­sa 2.0 with a twist: Medicxi com­bines six im­muno-derm star­tups with $100M

Kyle LaHucik

Senior Reporter

Eu­ro­pean biotech in­vestor Medicxi is bring­ing six star­tups un­der one roof to form an im­muno-der­ma­tol­ogy drug­mak­er with 14 pipeline projects in a move rem­i­nis­cent of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times